---
title: "European stocks \"Eleven Arhats\" closing report | ASML rose over 35.7% for the year, Novo Nordisk fell about 47.9%"
description: "On Wednesday (December 31), ASML Holding A) rose by 0.33%, with a cumulative increase of 35.76% for the year. Novo Nordisk (NOVOB.DC) fell by 47.89% for the year. SAP (SAP.GR) fell by 11.83%. L'Oréal "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271238405.md"
published_at: "2025-12-31T18:31:19.000Z"
---

# European stocks "Eleven Arhats" closing report | ASML rose over 35.7% for the year, Novo Nordisk fell about 47.9%

> On Wednesday (December 31), ASML Holding A) rose by 0.33%, with a cumulative increase of 35.76% for the year. Novo Nordisk (NOVOB.DC) fell by 47.89% for the year. SAP (SAP.GR) fell by 11.83%. L'Oréal (OR.FP) rose by 7.24%. LVMH (MC.FP) rose by 1.49%. Sanofi (SAN.FP) fell by 11.75%. Novartis (NOVN.SW) rose by 23.56%, Roche (ROG.SW) rose by 28.45%, and Nestlé (NESN.SW) rose by 5.15%. AstraZeneca (AZN.LN) rose by 31.73%. GlaxoSmithKline (GSK.LN) rose by 35.50%

On Wednesday (December 31), ASML Holding's stock price in Amsterdam (ASML.NA) closed up 0.33% at €921.40, with a cumulative increase of nearly 35.76% in 2025.  
The Danish stock market was closed, with Novo Nordisk's stock price in Copenhagen (NOVOB.DC) down over 47.89% for the year.  
The German stock market was closed, with SAP (SAP.GR) down nearly 11.83% for the year.  
L'Oréal (OR.FP) closed down 0.10%, with a cumulative increase of 7.24% for the year.  
LVMH Group (MC.FP) closed up 0.89%, with a cumulative increase of over 1.49% for the year.  
Sanofi (SAN.FP) closed down 0.34%, with a cumulative decrease of over 11.75% for the year.  
The Swiss stock market was closed, with Novartis (NOVN.SW) up over 23.56% for the year, Roche Holding (ROG.SW) up over 28.45%, and Nestlé (NESN.SW) up over 5.15%.  
AstraZeneca (AZN.LN) closed up 0.29%, with a cumulative increase of over 31.73% for the year.  
GlaxoSmithKline's stock price in London (GSK.LN) closed down 0.33%, with a cumulative increase of about 35.50% for the year

### Related Stocks

- [NVS.US - NOVARTIS AG](https://longbridge.com/en/quote/NVS.US.md)
- [ASML.US - ASML](https://longbridge.com/en/quote/ASML.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)
- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4% | 诺和诺德 ADR 恢复交易，瞬间跳水，跌幅扩大至 8.4%。风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此 | [Link](https://longbridge.com/en/news/274689185.md) |
| Lafayette Investments Inc. 增加了其在 ASML Holding N.V. $ASML 的持股量 | 拉法叶投资公司在第三季度将其在 ASML Holding N.V.的持股增加了 63.3%，目前持有 2,400 股，价值 232 万美元。其他对冲基金也增加了在 ASML 的投资。该股票开盘价为 1,406.87 美元，市值为 5,532 | [Link](https://longbridge.com/en/news/275896624.md) |
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 欧莱雅首席执行官：对护肤品表现不满意，我们在过去 8 年中一直领先于市场，但在 2025 年将不再如此 | 欧莱雅首席执行官：对护肤品不满意，我们在市场上领先了 8 年，但在 2025 年却没有 | [Link](https://longbridge.com/en/news/275883512.md) |
| 葛兰素史克的 RSV 疫苗 Arexvy 已被中国接受进行监管审查 | 中国药品监管机构已接受葛兰素史克（GSK plc）针对 RSV 疫苗 Arexvy 的监管审查申请。该疫苗旨在预防 60 岁及以上成年人因呼吸道合胞病毒（RSV）引起的下呼吸道疾病。如果获得批准，它将成为中国首个针对该年龄组的 RSV 疫苗 | [Link](https://longbridge.com/en/news/275415505.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.